Home・Akciju saraksts・AtriCure Inc

AtriCure Inc

Atvērts

SektorsVeselības aprūpe

39.02 1.51

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

38.35

Max

39.19

Galvenie mērījumi
By Trading Economics
Ienākumi	8.8M 9M
Pārdošana	12M 154M
P/E Sektora vidējais	177.952 64.641
EPS	0.18
Peļņas marža	5.83
Darbinieki	1,350
EBITDA	-3.8M 3.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+22.13% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 28. okt.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	132M 1.9B
Iepriekšējā atvēršanas cena	37.51
Iepriekšējā slēgšanas cena	39.02

Ziņu noskaņojums

By Acuity

34%

66%

104 / 340 Rangs Healthcare

AtriCure Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. aug. 20:06 UTC

AtriCure Inc. shares are higher during Monday's session, regaining ground after an earlier pullback. Broader market trends support positive investor sentiment.

2026. g. 31. jūl. 20:03 UTC

News

AtriCure shares are lower amid significant insider selling, including a $233,280 sale by Chief Scientific Officer Vinayak Doraiswamy and options exercised by Board Member Sven Wehrwein.

2026. g. 30. jūl. 18:56 UTC

AtriCure Inc's shares are lower today, impacted by declines in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

2026. g. 29. jūl. 20:03 UTC

News

AtriCure Inc shares reached a 52-week high of $43.18 following better-than-expected quarterly earnings, despite a pullback earlier in the session.

2026. g. 28. jūl. 19:21 UTC

AtriCure Inc's shares are higher today amid stronger gains in U.S. and European indices, with no specific company news identified for the movement.

2026. g. 27. jūl. 20:02 UTC

News

AtriCure Inc shares are higher as the company prepares for two investor conferences and highlights CEO Michael Carrel's leadership appointment.

2026. g. 24. jūl. 21:41 UTC

AtriCure Inc. shares traded roughly flat in after-market hours. The stock has performed well recently, positioned near the upper end of its monthly range.

2026. g. 23. jūl. 21:51 UTC

News

AtriCure reported strong Q2 results and raised EPS guidance but shares fell in after-market trading, marking the sixth consecutive session of declines.

2026. g. 22. jūl. 19:56 UTC

AtriCure Inc shares are trading lower, reaching a session low just before 15:30 ET, despite remaining above the 20-day moving average.

2026. g. 21. jūl. 19:16 UTC

AtriCure Inc shares are trading lower today, continuing a trend of declines over the past three sessions, despite gains in the Nasdaq 100 Index.

2026. g. 20. jūl. 19:51 UTC

AtriCure Inc continues higher today, maintaining strength since Friday's close, despite a recent pullback earlier in the session.

Salīdzinājums

Cenas izmaiņa

AtriCure Inc Prognoze

Cenas mērķis

By TipRanks

22.13% augšup

Prognoze 12 mēnešiem

Vidējais 47.29 USD 22.13%

Augstākais 55 USD

Zemākais 36 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AtriCure Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam AtriCure Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

104 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par AtriCure Inc

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.